Findings

What do systematic reviews say?

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Diclofenac vs placebo

Reduction in pain intensity · children with acute postoperative pain

2 findings from 1 review

Diclofenac for acute postoperative pain in children 2023 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported
Diclofenac for acute postoperative pain in children 2023 · Cochrane Headline outcomes only
no estimate extracted
2 participants
GRADE not reported

Diclofenac vs placebo

Nausea and vomiting · children with acute postoperative pain

It is very uncertain whether diclofenac changes nausea, vomiting, or both during study period № of participants:… compared with placebo (very low certainty).

1 finding from 1 review

Diclofenac for acute postoperative pain in children 2023 · Cochrane Headline outcomes only
RR 0.83 [0.38, 1.8]
2 studies · 100 participants
Very low

Diclofenac vs placebo

Any bleeding during study period № of participants: 100(2 RCTs)d · children with acute postoperative pain

It is very uncertain whether diclofenac changes any bleeding during study period № of participants: 100(2 RCTs)d compared with placebo (very low certainty).

1 finding from 1 review

Diclofenac for acute postoperative pain in children 2023 · Cochrane Headline outcomes only
RR 3 [0.34, 26.45]
2 studies · 100 participants
Very low

Diclofenac vs placebo

Serious adverse events during the study period · children with acute postoperative pain

The review found no eligible studies for this question.

1 finding from 1 review

Diclofenac for acute postoperative pain in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical ophthalmic anesthetic vs placebo or NSAID

Changes in mean participant‐reported ocular pain from baseline to 24 hours · corneal abrasion (post‐trauma or post‐surgical)

1 finding from 1 review

Topical ophthalmic anesthetics for corneal abrasions 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Topical ophthalmic anesthetic plus NSAID vs placebo

Proportion of participants with complications at longest time point Up to 1 week · corneal abrasion (post‐surgical)

1 finding from 1 review

Topical ophthalmic anesthetics for corneal abrasions 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Topical ophthalmic anesthetic vs placebo or NSAID

Changes in mean participant‐reported ocular pain from baseline to 48 hours · corneal abrasion (post‐trauma or post‐surgical)

1 finding from 1 review

Topical ophthalmic anesthetics for corneal abrasions 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Topical ophthalmic anesthetic vs placebo or NSAID

Changes in mean participant‐reported ocular pain from baseline to 72 hours · corneal abrasion (post‐trauma or post‐surgical)

1 finding from 1 review

Topical ophthalmic anesthetics for corneal abrasions 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

Topical ophthalmic anesthetic vs placebo or NSAID

Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours · corneal abrasion (post‐trauma or post‐surgical)

1 finding from 1 review

Topical ophthalmic anesthetics for corneal abrasions 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Topical ophthalmic anesthetic vs placebo or NSAID

Proportion of participants with complications at longest time point Up to 2 weeks · corneal abrasion (post‐trauma or post‐surgical)

1 finding from 1 review

Topical ophthalmic anesthetics for corneal abrasions 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Topical ophthalmic anesthetic plus NSAID vs placebo

Changes in mean participant‐reported ocular pain from baseline to 24 hours · corneal abrasion (post‐surgical)

1 finding from 1 review

Topical ophthalmic anesthetics for corneal abrasions 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Topical ophthalmic anesthetic plus NSAID vs placebo

Changes in mean participant‐reported ocular pain from baseline to 48 hours · corneal abrasion (post‐surgical)

The review found no eligible studies for this question.

1 finding from 1 review

Topical ophthalmic anesthetics for corneal abrasions 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical ophthalmic anesthetic plus NSAID vs placebo

Changes in mean participant‐reported ocular pain from baseline to 72 hours · corneal abrasion (post‐surgical)

The review found no eligible studies for this question.

1 finding from 1 review

Topical ophthalmic anesthetics for corneal abrasions 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical ophthalmic anesthetic plus NSAID vs placebo

Proportion of participants without complete resolution of epithelial defects by 24 to 72 hours · corneal abrasion (post‐surgical)

It is very uncertain whether topical ophthalmic anesthetic plus NSAID changes proportion of participants without complete resolution of epithelial… compared with placebo (very low certainty).

1 finding from 1 review

Topical ophthalmic anesthetics for corneal abrasions 2023 · Cochrane Headline outcomes only
RR 0.33 [0.04, 2.85]
1 study · 30 participants
Very low

Anticoagulant vs placebo or no treatment

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.04, 3.61]
5 studies · 1777 participants
Low

Anticoagulant vs placebo or no treatment

Venous thromboembolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant probably leads to lower venous thromboembolism compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.16, 0.85]
4 studies · 1259 participants
Moderate

Anticoagulant vs placebo or no treatment

Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in major bleeding compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.01, 8.78]
5 studies · 1777 participants
Low

Anticoagulant vs placebo or no treatment

Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in deep vein thrombosis compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 1.02 [0.3, 3.46]
3 studies · 1009 participants
Moderate

Anticoagulant vs placebo or no treatment

Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant probably leads to lower pulmonary embolism compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.25 [0.08, 0.79]
3 studies · 1009 participants
Moderate

Anticoagulant vs placebo or no treatment

Need for hospitalisation · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in need for hospitalisation compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 1.01 [0.59, 1.75]
4 studies · 1459 participants
Moderate